2025
Transcriptomic analysis reveals shared deregulated neutrophil responses in COVID-19 and idiopathic pulmonary fibrosis
Divolis G, Synolaki E, Tringidou R, Tzouvelekis A, Boumpas D, Skendros P, Galani I. Transcriptomic analysis reveals shared deregulated neutrophil responses in COVID-19 and idiopathic pulmonary fibrosis. Respiratory Research 2025, 26: 213. PMID: 40500689, PMCID: PMC12160113, DOI: 10.1186/s12931-025-03180-2.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosis patientsIdiopathic pulmonary fibrosisNeutrophil extracellular trapsPulmonary fibrosisIPF pathophysiologyPeripheral blood neutrophil countElevated peripheral blood neutrophil countsAcute respiratory distress syndromeCOVID-19 neutrophilsPeripheral blood of COVID-19 patientsLung biopsy specimensBlood of COVID-19 patientsRespiratory distress syndromeDeregulated immune responseNeutrophil extracellular trap formationBlood neutrophil countNeutrophil-driven pathologiesCOVID-19 pathogenesisCOVID-19 patientsLung biopsyBiopsy specimensDistress syndromePeripheral bloodNeutrophil countActivin/follistatin system
2023
Pathophysiology and clinical management of coronavirus disease (COVID-19): a mini-review
Zhu Y, Sharma L, Chang D. Pathophysiology and clinical management of coronavirus disease (COVID-19): a mini-review. Frontiers In Immunology 2023, 14: 1116131. PMID: 37646038, PMCID: PMC10461092, DOI: 10.3389/fimmu.2023.1116131.Peer-Reviewed Original ResearchConceptsClinical managementAppropriate host immune responseSevere acute pneumoniaMultiple organ failureCOVID-19 pathogenesisSecondary bacterial infectionLower respiratory systemSpecific pathogenic mechanismsHost immune responseLife-threatening consequencesCOVID-19SARS-CoV-2Spread of infectionOrgan failureAcute pneumoniaExcessive inflammationInfected subjectsSystemic diseaseProtease TMPRSS2Mild infectionImmune responseHealthcare threatPathogenic mechanismsTherapeutic paradigmBacterial infectionsStudies in humans and mice reveal a critical role for CCR2 in trafficking of pDCs during infection with SARS-CoV-2
Zhang H, Lu X, Garner D, Parween F, Singh S, Majumdar S, Weaver J, Stein S, Lesho P, Damcott C, Lutfi F, Petrick K, Rock P, Chertow D, Kelsall B, Murphy P, Dahiya S, Hardy N, Farber J. Studies in humans and mice reveal a critical role for CCR2 in trafficking of pDCs during infection with SARS-CoV-2. The Journal Of Immunology 2023, 210: 143.04-143.04. DOI: 10.4049/jimmunol.210.supp.143.04.Peer-Reviewed Original ResearchMAIT cellsSARS-CoV-2Chemokine receptorsCCR2-deficient miceHospitalized COVID-19 patientsCOVID-19 pathogenesisBlood pDCCOVID-19 patientsReporter miceAffecting disease severityCCR2 ligandsCCR2III interferonsBlood leukocytesType 1ChemokinesDisease severityIncreased MortalityBlood cellsReceptorsAbsolute numberLeukocyte extravasationLungTransendothelial migrationBlood
2022
A glucose-like metabolite deficient in diabetes inhibits cellular entry of SARS-CoV-2
Tong L, Xiao X, Li M, Fang S, Ma E, Yu X, Zhu Y, Wu C, Tian D, Yang F, Sun J, Qu J, Zheng N, Liao S, Tai W, Feng S, Zhang L, Li Y, Wang L, Han X, Sun S, Yang L, Zhong H, Zhao J, Liu W, Liu X, Wang P, Li L, Zhao G, Zhang R, Cheng G. A glucose-like metabolite deficient in diabetes inhibits cellular entry of SARS-CoV-2. Nature Metabolism 2022, 4: 547-558. PMID: 35534727, DOI: 10.1038/s42255-022-00567-z.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Diabetes mellitusDiabetic micePre-existing medical comorbiditiesSARS-CoV-2 infectionSARS-CoV-2 replicationRespiratory tissue damageSevere COVID-19COVID-19 pathogenesisHigh viral loadWild-type miceSARS-CoV-2 loadSARS-CoV-2 spike proteinCOVID-19Effective antiviral activityMedical comorbiditiesDiabetic populationDiabetic patientsNondiabetic miceViral loadAG supplementationSustained supplementationAg levelsHealthy individualsViral infection
2021
Potential role of IFN-α in COVID-19 patients and its underlying treatment options
Yang L, Wang J, Hui P, Yarovinsky TO, Badeti S, Pham K, Liu C. Potential role of IFN-α in COVID-19 patients and its underlying treatment options. Applied Microbiology And Biotechnology 2021, 105: 4005-4015. PMID: 33950278, PMCID: PMC8096625, DOI: 10.1007/s00253-021-11319-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSARS-CoV-2 infectionIFN-α subtypesRespiratory virus diseasesCOVID-19 patientsImmunoregulatory effectsInflammatory responseSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2COVID-19 pathogenesisTreatment of patientsUncontrolled inflammatory responseSyndrome coronavirus 2Interferon-stimulated gene expressionPotential therapeutic strategySeverity of infectionSARS-CoV-2Virus diseaseInnate immune systemPossible side effectsCOVID-19 diseaseViral infection treatmentDrug candidatesCoronavirus 2Treatment optionsDiverse Functional Autoantibodies that Underlie Immune Perturbations in COVID-19
Mao T, Wang E, Klein J, Dai Y, Huck J, Liu F, Zheng N, Zhou T, Goldman-Israelow B, Wong P, Lucas C, Silva J, Oh J, Song E, Perotti E, Fischer S, Campbell M, Fournier J, Wyllie A, Vogels C, Ott I, Kalinich C, Petrone M, Watkins A, Cruz C, Farhadian S, Schulz W, Grubaugh N, Ko A, Iwasaki A, Ring A. Diverse Functional Autoantibodies that Underlie Immune Perturbations in COVID-19. The Journal Of Immunology 2021, 206: 114.04-114.04. DOI: 10.4049/jimmunol.206.supp.114.04.Peer-Reviewed Original ResearchSARS-CoV-2 infectionClinical outcomesSARS-CoV-2 resultsPre-existing autoantibodiesPrevalence of autoantibodiesAntiviral antibody responseCOVID-19 pathogenesisCOVID-19 patientsCOVID-19SARS-CoV-2COVID-19 diseaseFunctional autoantibodiesMurine surrogateAutoantibody responseImmune activationImmune perturbationsAutoantibody repertoireAntibody responseAutoantibody targetsSevere diseaseImmunological functionsAutoantibodiesMouse modelUninfected controlsAbstract InfectionType I Interferon Shapes Humoral Immunity to SARS-CoV-2
Goldman-Israelow B, Mao T, Song E, Lu P, Wong P, Lucas C, Klein J, Iwasaki A. Type I Interferon Shapes Humoral Immunity to SARS-CoV-2. The Journal Of Immunology 2021, 206: 114.07-114.07. DOI: 10.4049/jimmunol.206.supp.114.07.Peer-Reviewed Original ResearchSARS-CoV-2 infectionIFN-I levelsFollicular helper T cellsSARS-CoV-2Helper T cellsRole of IFNType I interferonT cellsI interferonSARS-CoV-2 antibodiesSARS-CoV-2 IgGSARS-CoV-2 S1Anti-S1 IgAIFNAR-deficient miceCOVID-19 pathogenesisCOVID-19 patientsHumoral immune responsePotent antibody responsesAntibody-secreting cellsCOVID-19 morbidityGerminal center B cellsPlasma IFNIgG levelsLymph nodesHumoral immunityNonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and Antibody Response to SARS-CoV-2 Infection
Chen JS, Alfajaro MM, Chow RD, Wei J, Filler RB, Eisenbarth SC, Wilen CB. Nonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and Antibody Response to SARS-CoV-2 Infection. Journal Of Virology 2021, 95: 10.1128/jvi.00014-21. PMID: 33441348, PMCID: PMC8092681, DOI: 10.1128/jvi.00014-21.Peer-Reviewed Original ResearchSARS-CoV-2 infectionNonsteroidal anti-inflammatory drugsCOVID-19 pathogenesisSARS-CoV-2Anti-inflammatory drugsProduction of prostaglandinsCyclooxygenase-2Immune responseNSAID treatmentCyclooxygenase-1Enzymes cyclooxygenase-1Inflammatory responseAbility of NSAIDsAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionSARS-CoV-2 vaccinationViral replicationPro-inflammatory cytokine responseCoronavirus 2 infectionExpression of angiotensinRelief of painPro-inflammatory cytokinesCoronavirus disease 2019 (COVID-19) pandemicHumoral immune response
2020
Circulating markers of angiogenesis and endotheliopathy in COVID‐19
Pine AB, Meizlish ML, Goshua G, Chang C, Zhang H, Bishai J, Bahel P, Patel A, Gbyli R, Kwan JM, Won CH, Price C, Dela Cruz CS, Halene S, van Dijk D, Hwa J, Lee AI, Chun HJ. Circulating markers of angiogenesis and endotheliopathy in COVID‐19. Pulmonary Circulation 2020, 10: 1-4. PMID: 33282193, PMCID: PMC7691906, DOI: 10.1177/2045894020966547.Peer-Reviewed Original ResearchCOVID-19 infectionMarkers of angiogenesisEndothelial injuryDisease severityCOVID-19-associated coagulopathyCritical COVID-19 infectionCOVID-19 pathogenesisCOVID-19COVID-19 diseaseEndothelial cell functionHospital mortalityMicrovascular complicationsCritical illnessElevated markersHospitalized patientsPatient populationFuture therapiesPlasma profilingSurvival analysisPatientsInfectionCell functionPotential targetInjuryMarkersAn updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic
Jamwal S, Gautam A, Elsworth J, Kumar M, Chawla R, Kumar P. An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic. Life Sciences 2020, 257: 118105. PMID: 32687917, PMCID: PMC7366108, DOI: 10.1016/j.lfs.2020.118105.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsSARS-CoV-2Secondary complicationsPathogenic SARS-CoV-2Hospitalized COVID-19 patientsRecovered COVID-19 patientsCOVID-19Brief clinical updatesNew SARS-CoV-2 virusCOVID-19 pathogenesisACE-2Broad-spectrum antiviral drugsCOVID-19 infectionCoronavirus disease 2019Vaccines/drugsSARS-CoV-2 virusHepatic complicationsViral burdenConvalescent plasmaClinical updateAngiotensin IIImmune damageEpidemiological featuresClinical trialsDisease 2019Treatment of COVID‐19 with pentoxifylline: Could it be a potential adjuvant therapy?
Seirafianpour F, Mozafarpoor S, Fattahi N, Sadeghzadeh‐Bazargan A, Hanifiha M, Goodarzi A. Treatment of COVID‐19 with pentoxifylline: Could it be a potential adjuvant therapy? Dermatologic Therapy 2020, 33: e13733. PMID: 32473070, PMCID: PMC7300917, DOI: 10.1111/dth.13733.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply